0749 GMT - Revenue from Roche's Tecentriq drug is unlikely to significantly increase despite data showing that in combination with lurbinectedin, it prolongs the life of patients with small-cell lung cancer, Vontobel analyst Stefan Schneider writes. Tecentriq was already approved in 2019 for use in combination with chemotherapy, he writes. Data from Roche shows that the median progression-free survival time was 5.4 months for the combination versus 2.1 months in the Tecentriq-alone arm, he writes. While this is an improvement, there is clearly room for more, he writes. Shares trade down 0.4% at 283.10 Swiss francs. (adam.whittaker@wsj.com)
(END) Dow Jones Newswires
June 03, 2025 03:51 ET (07:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。